Remepy develops hybrid drugs—therapeutic assets that combine conventional pharmaceutical agents with proprietary non‑pharmaceutical treatment protocols.
The company applies AI-driven measurement and adaptation to deliver and optimize those protocols, operating at the intersection of drug development, digital therapeutics, and treatment personalization.
Leadership & Board
Key Executives
FounderMichal Tsur and Or Shoval
CSOAmir Amedi
CTOEran Etam
Current Number of Employees86
Current LinkedIn Followers7,412
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$46M
Total Amount Raised$46M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$36M
Latest Funding Amount$36M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Remepy had 86 employees as of August 31, 2026. The number of employees increased by 1 (1.18%) week-over-week.
86Latest Employee Count
1(1.18%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Remepy had 7,412 followers as of August 31, 2026. The number of followers increased by 97 (1.33%) week-over-week.
7,412Latest Followers Count
97(1.33%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.